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Abstract
A vast number of small-molecule ligands, including therapeutic drugs under development and in
clinical use, elicit their effects by binding specific proteins associated with the genome. An ability
to map the direct interactions of a chemical entity with chromatin genome-wide could provide new
and important insights into chemical perturbation of cellular function. Here we describe a method
that couples ligand-affinity capture and massively parallel DNA sequencing (Chem-seq) to
identify the sites bound by small chemical molecules throughout the human genome. We show
how Chem-seq can be combined with ChIP-seq to gain unique insights into the interaction of
drugs with their target proteins throughout the genome of tumor cells. These methods provide a
powerful approach to enhance understanding of therapeutic action and characterize the specificity
of chemical entities that interact with DNA or genome-associated proteins.
The ability to map the locations of proteins throughout the genome has had a profound
impact on our understanding of a wide range of normal and disease biology. For example,
discovery of the genome-wide location of proteins using ChIP-seq has allowed global
6These authors contributed equally to this work
Accession Codes: Chem-seq and ChIP-seq data, GEO: GSE44098 and GSE43743, respectively.
Author Contributions: J.J.M., P.B.R., J.E.B. and R.A.Y. conceived of the Chem-seq method, L.A. and M.G.G. developed the
method, L.A. generated bio-JQ1 and bio-psoralen Chem-seq data, M.G.G. generated bio-AT7519 Chem-seq data, Z.P.F. developed
computational methods and analyzed the data, J.Q. and J.J.M. synthesized biotinylated derivatives of chemical probes, J.Q. performed
protein biochemistry, L.A., P.B.R. and J.L. generated ChIP-seq data for BRD2, BRD3, BRD4, RNA pol II, CDK7, CDK8 and CDK9,
W.B.S. generated cellular proliferation data, A.A.S. contributed to optimize Chem-seq, T.I.L. provided advice on method
development, and J.E.B. and R.A.Y. supervised the research.
Competing Financial Interests: J.E.B. and R.A.Y. are founders of Syros Pharmaceuticals. J.J.M., P.B.R., M.G.G. and J.L. are
employees of Syros Pharmaceuticals.
NIH Public Access
Author Manuscript
Nat Biotechnol. Author manuscript; available in PMC 2014 October 08.
Published in final edited form as:
Nat Biotechnol. 2014 January ; 32(1): 92–96. doi:10.1038/nbt.2776.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tmapping of the key transcription factors and chromatin regulators that control gene
expression programs in various cells, the sites that act as origins of DNA replication, and
regions of the genome that form euchromatin and heterochromatin1-6. Models of the
transcriptional regulatory circuitry that controls normal and disease cell states have emerged
from genome-wide data7-10.
An ability to map the global interactions of a chemical entity with chromatin genome-wide
could provide new insights into the mechanisms by which a small molecule influences
cellular functions. Many DNA-associated processes are targeted for disease therapy,
including transcription, modification, replication and repair11-16. Ligand-affinity
methodologies have greatly contributed to our understanding of drug and ligand function at
the genome, and have led to the identification of numerous gene regulatory drug targets17-20.
There have been initial efforts to map the sites of interaction of metabolic compounds in the
yeast genome21, but it would be ideal to have a method that allows investigators to
determine how small-molecule therapeutics interact with the human genome. We describe
here a method based on chemical affinity capture and massively parallel DNA sequencing
(Chem-seq) that allows investigators to identify genomic sites where small chemical
molecules interact with their target proteins or DNA (Fig. 1a). The Chem-seq method is
similar to that employed for ChIP-seq, except that Chem-seq uses retrievable synthetic
derivatives of a compound of interest to identify sites of genome occupancy whereas ChIP-
seq uses antibodies against specific proteins for this purpose.
We used Chem-seq to investigate the genome-wide binding of the bromodomain inhibitor
JQ1 to the BET bromodomain family members BRD2, BRD3 and BRD4 in MM1.S multiple
myeloma cells. JQ1 was previously been shown to bind all three co-activator proteins and to
inhibit growth of MM1.S and other tumor cells13, 22-27. We first investigated how BRD2,
BRD3 and BRD4 occupy the genome of MM1.S cells using ChIP-Seq (Supplementary Fig.
1). All three proteins were found to be associated with actively transcribed genes
(Supplementary Fig. 1a). Inspection of individual gene tracks (Supplementary Fig. 1b) and
analysis of global genome occupancy (Supplementary Fig. 1c) showed that most core
promoter elements of active genes were co-occupied by BRD2, BRD3 and BRD4 together
with RNA polymerase II, the Mediator coactivator and histone H3K27Ac. In contrast,
enhancers, which are occupied by histone H3K27Ac and Mediator, were preferentially
occupied by BRD4, with lower relative levels of BRD2 and BRD3.
To investigate the interaction of JQ1 with chromatin genome-wide, we used the Chem-seq
technique (Fig. 1a) with a biotinylated derivative of JQ1 (bio-JQ1, Fig. 1b). Enantioretentive
substitution at C-6 of the JQ1 diazepine allowed coupling of a poly-ethylene glycol spacer
with appended biotin feature. The potency of bio-JQ1 binding to the first bromodomain of
BRD4 was nearly equivalent to the unbiotinylated compound, as determined by both
differential scanning fluorimetry and isothermal titration calorimetry (Supplementary Fig.
2). Consistent with this, bio-JQ1 had only slightly reduced bioactivity in MM1.S cells
relative to JQ1 (Fig. 1c). We initially treated living cells with bio-JQ1 and cross-linked
proteins to DNA with formaldehyde (in vivo Chem-seq, Fig. 1a, upper panel). Cells were
then lysed, sonicated to shear the DNA and streptavidin beads were used to isolate
biotinylated ligand and associated chromatin fragments. Massively parallel sequencing was
Anders et al. Page 2
Nat Biotechnol. Author manuscript; available in PMC 2014 October 08.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tused to identify enriched DNA fragments, and these sequences were mapped to the genome
to reveal sites bound by the small molecule probe.
In addition, we developed an in vitro version of this method, which allows analysis of
biotinylated molecules with potentially limited cell permeability (in vitro Chem-seq, Fig. 1a,
lower panel). To this end, MM1.S cells were fixed and the derived sonicated lysate
incubated with biotinylated JQ1 to enrich for bound chromatin regions in vitro.
We found that both in vivo and in vitro Chem-seq produced essentially the same result: the
genomic sites bound by biotinylated JQ1 are highly similar to the sites occupied by BRD2,
BRD3 and BRD4 (Fig. 1d, e). This was further confirmed by inspection of data at individual
genes with pivotal roles in myeloma biology, such as CCND2 (Fig. 1f). By contrast, a
functionally inactive enantiomer of bio-JQ1 (bio-JQ1R, Supplementary Fig. 3a) did not
produce significant Chem-seq signals (Supplementary Fig. 3b, c). These results indicate that
both live-cell and cell-lysate based Chem-seq approaches (Fig. 1a) can be used to uncover
the interactions of small molecules with their chromatin targets across the human genome.
Of note, JQ1 is known to displace BET bromodomains from the genome, but the ability to
detect the bio-JQ1/BRD complex on chromatin is likely made possible by covalent tethering
of these proteins to chromatin during fixation (Supplementary Fig. 4).
We next investigated the extent to which Chem-seq and ChIP-seq signals overlap (Fig. 2).
The pattern of JQ1 occupancy was best associated with the pattern of BRD4 occupancy (Fig.
2a). Pearson correlation analysis also showed that bio-JQ1 signals were most highly
correlated with BRD4, somewhat less frequently with BRD2 and much less frequently with
BRD3 (Fig. 2b). We then developed a generalized linear model (GLM) to identify genomic
regions with differential signal between bio-JQ1 Chem-seq and each of the BRD ChIP-seq
datasets. We found that bio-JQ1 co-occupied nearly all regions (>99%) with BRD4 genome-
wide across triplicate datasets, bio-JQ1 and BRD2 co-occupied 96% of all genomic sites,
and bio-JQ1 and BRD3 co-occupied 63% of all genomic sites (Fig. 2c). Inspection of gene
tracks for regions differentially occupied by bio-JQ1 and the three BET proteins provided
visual confirmation that bio-JQ1 tends to co-occupy enhancers where there are substantial
BRD4 signals and lower signals for BRD2 and BRD3 (Fig. 2d). The pattern of BRD3
genome occupancy differed most from that of the other two BET proteins (Fig. 2a–c), and
this was due to pronounced signals at a subset of core promoter sites (Fig 2e). Similar results
were obtained with an alternative BRD3 ChIP antibody directed against a different epitope
of this protein (Supplementary Fig. 5). Taken together, these results indicate that the pattern
of JQ1 occupancy of chromatin is most correlated with that of BRD4 in MM1.S cells,
consistent with the relative affinities of JQ1 for these BET proteins previously established in
vitro27.
To extend the Chem-seq method to other drug classes, we initially focused on AT7519, an
inhibitor of the cyclin-dependent kinase CDK9 (ref. 28), which is associated with the
transcription apparatus at promoters. CDK9 phosphorylation of RNA polymerase II and
various pause control factors stimulates active elongation29. We first confirmed that CDK9
co-occupies the promoters of active genes with RNA polymerase II by using ChIP-seq (Fig.
3a, b). CDK9 is a core component of the positive transcription elongation factor, p-TEFb29,
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tand its inhibition would be expected to affect the levels of elongating RNA polymerase II,
which is located across the body of genes, to a much greater extent than the levels of
initiating RNA polymerase located at the transcription start site. Indeed, treatment of
MM1.S cells with AT7519 was found to cause a reduction in the level of elongating RNA
polymerase II based on examination of individual gene tracks (Fig. 3c) and on analysis of
the ratio of initiating versus elongating RNA polymerase II molecules at active genes
throughout the genome (Fig. 3d). We next generated a retrievable biotinylated derivative of
AT7519 (Fig. 3e). The biotinylated compound was found to have reduced ability to enter
cells (Fig. 3f, g), so we used the in vitro Chem-seq method to investigate binding of bio-
AT7519 to chromatin genome-wide. The results show that bio-AT7519 Chem-seq signals
occur frequently at sites occupied by CDK9 (Fig. 3h, i). The bio-AT7519 Chem-seq signals
were weaker than those observed for bio-JQ1, which may reflect differences in accessibility,
association constants, or ligand-receptor sensitivity to sample preparation. Nonetheless,
there was a correlation between bio-AT7519 occupancy and CDK9 occupancy genome-wide
(Supplementary Fig. 6a). There were also a substantial number of sites that were not co-
occupied by bio-AT7519 and CDK9; it is possible that this is due to the relatively weak
signals we obtained for bio-AT7519 Chem-seq or to the fact that AT7519 can inhibit other
kinases28, 30 that may occupy other genomic sites (Supplementary Fig. 6b). Notably, a
comparison of the Chem-seq data for bio-AT7519 and bio-JQ1 with ChIP-seq data for
various components of the transcription apparatus (CDK7, CDK8, CDK9, RNA Polymerase
II, Mediator and BRD4) revealed that bio-AT7519 was most associated with CDK9,
whereas bio-JQ1 was most associated with BRD4 (Supplementary Fig. 6c). These results
suggest that Chem-seq can be useful for identifying the genomic binding sites of kinase
inhibitors.
To further extend the Chem-seq method to other drug classes, we investigated how the DNA
intercalator psoralen interacts with genomic DNA in vivo. Recent studies have shown that
psoralen preferentially intercalates at the transcriptional start sites (TSS) of active
genes31, 32. We used the in vivo Chem-seq method with biotinylated psoralen (bio-psoralen)
(Fig. 3j) to explore this observation genome-wide in MM1.S cells. The results confirm that
bio-psoralen preferentially binds to the TSS of active genes (Fig. 3k–m). Thus, Chem-seq
can detect local enrichment of DNA intercalating agents throughout the human genome.
A broad range of drugs should generally be amenable to biotinylation and Chem-seq
analysis. The design and synthesis of biotinylated probes can be informed by structural data
from drug-target complexes; such X-ray structures allow the identification of suitable
attachment positions that can be covalently linked to the biotin moiety and that remain freely
accessible in the complex. Suitable attachment points could also be inferred from structure-
activity relationship data derived from structurally related compounds. If such data are not
available, several attachment sites can be selected for biotinylation, and the derived probes
can be tested experimentally for their ability to retain binding to the target. Points of
attachment can either be provided by functional groups already present in the drug molecule,
or may be obtained through chemical modification of the compound structure, such as
alkylation or addition of amide or ester linkages. Finally, as there is an expanding interest in
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telucidating the mechanisms of action of many drugs, biotinylated versions of such
compounds are increasingly becoming commercially available.
In summary, Chem-seq provides a method to identify the sites bound by small chemical
molecules throughout the human genome. When combined with other global analysis
methods such as ChIP-seq, Chem-seq provides a powerful approach to investigate the direct,
genome-wide effects of therapeutic modalities. This ability to map the global interactions of
a chemical entity with chromatin genome-wide should provide new insights into the
mechanisms by which small molecules perturb gene expression programs.
Methods
Methods and associated references are available in the online version of the paper.
Online Methods
Commercially available compounds
AT7519 and biotinylated Psoralen (EZ-Link Psoralen-PEG-Biotin) were obtained from
Selleck Chemicals and Thermo Fisher Scientific, respectively.
Cell culture and treatment with unbiotinylated drugs
Multiple Myeloma MM1.S cells (CRL-2974, ATCC) were maintained in RPMI-1640
supplemented with 10% fetal bovine serum and 1% GlutaMAX (Invitrogen, 35050-061).
For JQ1 treatment experiments, asynchronous cells were treated with varying concentrations
of JQ1 or vehicle (DMSO) for 6. Alternatively, cells were treated with 2 μM AT7519 for 6h.
Genome-wide occupancy analysis of drug target proteins (ChIP-seq)
ChIP coupled with massively parallel DNA sequencing (ChIP-seq) was performed as
previously described33. The following antibodies were used for Chromatin
Immunoprecipitation (ChIP): anti-BRD4 (Bethyl Labs, A301-985A), anti-BRD2 (Cell
signaling, 5848), anti-BRD3 (Bethyl Labs, A302-367A and A302-368A), anti-MED1
(Bethyl Labs, A300-793A), anti-H3K27Ac (Abcam, ab4729), anti-RNA-pol II (Santa Cruz,
sc-899), anti-CTCF (Millipore, 07-729) and anti-CDK9 (sc-484). Illumina sequencing,
library construction and ChIP-seq analysis methods were previously described33.
Synthesis of bio-JQ1(S)
The synthesis of active bio-JQ1(bio-JQS) started with the (S)-JQ1, the active enantiomer that
inhibits the bromodomain extra-terminal (BET) subfamily. As shown in the schematic
below, removal of the tert-butyl group of the ester on (S)-JQ produced the acid S1. The
resulting acid was then coupled with mono-protected (PEG)2 linked diamine to give an
amide S2. The protecting group on the terminal amine of compound S2 was removed under
acidic condition to generate free amine, which was further coupled with biotin to afford the
final active bio-JQ1(bio-JQ1S). The biotinylated inactive enantiomer bio-JQ1(R) was
synthesized in the same synthetic route using inactive enantiomer (R)-JQ1.
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As illustrated in the schematic below, biotinylated AT7519 (bio-AT7519) was directly
synthesized from commercially available AT7519 (Selleck Chemicals) with Biotin-PEG2-
COOH by amide coupling catalyzed by HCTU in DMF.
Expression of recombinant BRD4(1)
The first bromodomain of BRD4 was purified as a poly-histidine-tagged recombinant human
protein expressed in E.coli, as previously described24.
Differential scanning fluorimetry
Thermal melting experiments were carried out using a 7300 Real Time PCR machine (AB
Applied Biosystems). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and
assayed in a 96-well plate at a final concentration of 1 μM in 20 μL volume. Compounds
were added at a final concentration of 10 μM. SYPRO Orange (Molecular Probes) was
added as a fluorescence probe at a dilution of 1:1000. Excitation and emission filters for the
SYPRO-Orange dye were set to 465 nm and 590 nm, respectively. The temperature was
raised with a step of 4 °C per minute from 25 °C to 96 °C and fluorescence readings were
taken at each interval. The observed temperature shifts, ΔTm obs, were recorded as the
difference between the transition midpoints of sample and reference (DMSO) wells
containing protein without ligand in the same plate.
Isothermal titration calorimetry
ITC was performed using a ITC200 microcalorimeter from MicroCal™(Northampton, MA).
All experiments were carried out at 25 °C while stirring at 1000 rpm, in ITC buffer (50 mM
HEPES pH 7.4 at 25 °C, 150 mM NaCl). The microsyringe was loaded with a solution of
the protein sample (190 μM, in ITC buffer). All titrations were conducted using an initial
injection of 0.2 μl, followed by 19 identical injections of 2 μl with a duration of 5 sec (per
injection) and a spacing of 90 sec between injections. The heat of dilution was determined
by independent titrations (protein into buffer) and was subtracted from the experimental
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tdata. The collected data were implicated in the MicroCal™ Origin software supplied with
the instrument to yield enthalpies of binding (ΔH) and binding constants. A single binding
site model was employed. Dissociation constants and thermodynamic parameters are
presented in Supplementary Fig. 2c.
In vivo genome-wide occupancy analysis of biotinylated JQ1 (In vivo Chem-seq)
Exponentially growing MM1.S cells (2×108 cells per sample) were treated simultaneously
with either 5 uM biotinylated JQ1 (Bio-JQ1) or DMSO (vehicle) and 1% Formaldehyde for
20 min in cell culture medium. Chemical crosslinking was terminated by addition of TRIS
buffer, pH 7.5, to a final concentration of 300mM TRIS. Cells were harvested using a silicon
scraper, centrifuged and the derived pellets washed three times with PBS. Cell nuclei were
prepared as follows: cells were lysed in 50 mM HEPES, pH 7.5, 140 mM NaCl, 1 mM
EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100 plus protease inhibitor cocktail
‘complete’ (Roche), and cell nuclei were washed once with 10 mM Tris-HCL, pH 8.0, 200
mM NaCl, 1 mM EDTA, 0.5 mM EGTA and protease inhibitors. Nuclei were resuspended
and sonicated in 50 mM Hepes-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS (sonication buffer) and protease
inhibitor cocktail at 18 W for 10 cycles (30 s each) on ice with 30 s intervals between cycles.
Sonicated lysates were cleared by centrifugation and incubated for 16 – 20 h at 4 °C with
magnetic Streptavidin Dynabeads (MyOne Streptavidin T1, Invitrogen) (beads were blocked
in PBS containing 0.5% BSA before this incubation step). Following incubation in nuclear
sonicated lysate, beads were washed twice in sonication buffer, once in sonication buffer
containing 500 mM NaCl, once in LiCl buffer (20 mM Tris-HCL, pH 8.0, 1 mM EDTA, 250
mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate), and once in 10 mM TRIS, pH 7.5, 0.1 mM
EDTA. Bound protein-DNA complexes were subsequently eluted in 50 mM Tris-HCL, pH
8.0, 10 mM EDTA, 10% SDS at 65 °C for 15 min, and crosslinks were reversed by
overnight incubation of the eluate at 65 °C. Contaminating RNA and protein were digested
by addition of RNase and Proteinase K, respectively, and the DNA purified as previously
described34. Finally, purified DNA fragments were massively parallel sequenced and the
sequencing data analyzed as described33.
In vitro genome-wide occupancy analysis of biotinylated JQ1 (In vitro Chem-seq)
Exponentially growing, untreated MM1.S cells were fixed with 1% Formaldehyde for 20
min in cell culture medium. Chemical crosslinking was terminated, cell nuclei prepared and
sonicated nuclear lysate obtained as described above. Unlike in the in vivo protocol,
however, Streptavidin Dynabeads were pre-incubated in PBS containing 0.5% BSA and
either 200 μM biotinylated drug or vehicle (DMSO) for 6 h. Drug-bound beads were
subsequently washed four times in PBS/0.5%BSA to remove unbound drug, and incubated
in nuclear sonicated lysate for 16 – 20 h at 4 °C. All following steps are identical to those
described above (in vivo Chem-seq method).
In vitro genome-wide occupancy analysis using biotinylated AT7519 (in vitro Chem-seq)
Exponentially growing, untreated MM1.S cells were fixed with 0.5% Formaldehyde for 5
min in cell culture medium. Chemical crosslinking was terminated by addition of TRIS
buffer, pH 7.5, to a final concentration of 300mM TRIS. Cells were washed 3× in PBS and
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tcell nuclei prepared as follows: Cell nuclei were lysed in 50 mM HEPES, pH 7.5, 140 mM
NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40, 0.25% Triton X-100 plus protease
inhibitor cocktail ‘complete’ (Roche), and cell nuclei were washed once with 10 mM Tris-
HCL, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and protease inhibitors. Nuclei
were resuspended and sonicated in 50 mM Hepes-KOH, pH 7.5, 140 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 0.5% NP-40, 0.5% Triton-X (sonication buffer). Pellets were
sonicated at 9-12 W for 4 cycles (30 s each) in a Misonix sonicator on ice with 1 min rest
intervals between cycles. Drug-bound beads were added to the cleared sonicate and the
precipitation allowed to proceed for 12-18 hours. Drug-bound beads were subsequently
washed four times in sonication buffer, proteins eluted in 1% SDS, and crosslinks were
reversed by overnight incubation of the eluate at 65 °C in 1% SDS. Contaminating RNA and
protein were digested by sequential incubation with RNase A and Proteinase K, and the
DNA purified as previously described34. Purified DNA fragments were subjected to
massively parallel sequencing (Illumina) and the sequencing data analyzed as described33.
In vitro genome-wide occupancy analysis of biotinylated psoralen by Chem-seq
Cell nuclei were prepared from exponentially growing MM.S cells using the Nuclei EZ prep
kit (SIGMA). Nuclei were then resuspended in ice-cold PBS and directly incubated with 5
μM biotinylated psoralen or vehicle (DMSO) for 30 min at 4 °C. Nuclei were washed once
in PBS and immediately irradiated at 360 nm for 30 min (Stratalinker) on ice. Nuclei were
resuspended and sonicated in 50 mM Hepes-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1
mM EGTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS (sonication buffer) and
protease inhibitor cocktail at 18 W for 10 cycles (30 s each) on ice with 30 s intervals
between cycles. Sonicated lysates were cleared by centrifugation and incubated for 16 – 20 h
at 4 °C with magnetic Streptavidin Dynabeads (MyOne Streptavidin T1, Invitrogen) (beads
were blocked in PBS containing 0.5% BSA before this incubation step). Following
incubation in nuclear sonicated lysate, beads were washed twice in sonication buffer, once in
sonication buffer containing 500 mM NaCl, once in LiCl buffer (20 mM Tris-HCL, pH 8.0,
1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate), and once in 10 mM
TRIS, pH 7.5, 0.1 mM EDTA. Bound protein-DNA complexes were subsequently eluted in
50 mM Tris-HCL, pH 8.0, 10 mM EDTA, 10% SDS and 10 mM Biotin, and the eluate
incubate do/n at 65 °C. Contaminating RNA and protein were digested by addition of RNase
and Proteinase K, respectively, and the DNA purified as previously described34. Finally,
purified DNA samples were irradiated at 254 nm for 5 min (Stratalinker) to reverse
psoralen-DNA crosslinks, followed by library preparation, massively parallel DNA
sequencing and analysis of sequencing data33.
Chem-seq and ChIP-seq data analysis
All ChIP-seq and Chem-seq datasets were aligned using Bowtie (version 0.12.2)35 to build
version NCBI36/HG18 of the human genome. We used the MACS version 1.4.1 (Model
based analysis of ChIP-seq)36 peak finding algorithm to identify regions of ChIP-seq
enrichment over background. A p-value threshold of enrichment of 1e-9 was used for all
datasets except for Chem-seq bioAT7519 (1e-6). To obtain the normalized read density of
ChIP-seq datasets in any region, ChIP-seq reads aligning to each region were extended
automatically by MACs, and the density of reads per basepair (bp) was calculated. The
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producing read density in units of reads per million mapped reads per bp (rpm/bp).
Definition of transcribed genes
A gene was defined as transcribed if an enriched region for either H3K4me3 or RNA Pol II
was located within ±5kb of the TSS. H3K4me3 is a histone modification associated with
transcription initiation37.
Definition of active enhancers
Active enhancers were defined as regions of enrichment for H3K27Ac outside of promoters
(greater than 2.5kb away from any TSS). H3K27Ac is a histone modification associated
with active enhancers38, 39. Active enhancers form loops with promoters that are facilitated
by the Mediator complex40. Thus, we validated H3K27Ac definitions of enhancers using
ChIP-Seq data for the mediator subunit Med1. Enriched regions from Med1 had >90%
overlap with H3K27Ac regions in all datasets.
Determination of RNA Pol II traveling ratio
We determined the ratio of RNA Pol II ChIP-seq levels in initiating to elongating regions, a
measure known as the traveling ratio (TR) (Fig. 3c and 3d)41. We defined the initiating
region as +/-300bp around the TSS. We defined the elongating region as +300bp from the
TSS to +3,000bp after the gene end. In order to make higher confidence comparisons, we
limited our analysis to genes with detectable signal above noise in the initiating and
elongating regions across all samples. The statistical significance of changes in the
distribution of traveling ratios was determined using two-tailed t test.
Heatmap representation of read density profiles
The enriched regions, the merged regions, or the annotated transcription start sites of all
refseq genes were aligned at the center in the composite view of signal density profile. The
average ChIP-Seq or Chem-seq read density (rpm/bp) around ±5kb centered on the centers
in 50 bp bin was calculated. The enriched regions of BRD2, BRD3, and BRD4 ChIP-seq
and bio-JQ1 Chem-seq were merged together if overlapping by 1bp, resulting a total of
25,450 merged regions. For bio-psorlen Chem-seq analysis, the annotated transcription start
sites of all refseq genes were used.
Pairwise comparison between Chem-seq and ChIP-seq
The set of genomic regions that were enriched for Chem-seq or ChIP-seq signal used in
pairwise comparisons were merged together if overlapping by 1bp. The average ChIP-Seq or
Chem-seq read density (RPM/PM) was calculated for each of the merged regions. The pair-
wise comparisons by Pearson correlation were performed on all datasets using the average
read density at the merged regions. The average linkage hierarchical clustering of the
Pearson correlation was shown in the heatmap (Supplementary Fig. 2b, 5a, and 6c). For Fig.
2b, the enriched regions of 3 replicate JQ1 in vitro Chem-seq datasets, 3 replicate BRD2
ChIP-seq datasets, 3 replicate BRD3 ChIP-seq datasets, and 3 replicate BRD4 ChIP-seq
datasets were merged together, resulting a total of 29,693 merged regions. For
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tSupplementary Fig. 5a, the enriched regions of bio-JQ1 (in vitro Chem-seq), BRD2, BRD3
from two different antibodies, and BRD4 (ChIP-seq) were merged together, resulting a total
of 25,693 merged regions. For Supplementary Fig. 6c, the enriched regions of CDK7,
CDK8, CDK8, BRD4, MED1, RNA pol II, H3K20me3, and H3K27me3 were merged
together, resulting a total of 50638 merged regions.
Specificity analysis based on overlap between Chem-seq and ChIP-seq data
We analyzed Chem-seq and ChIP-seq data to identify genomic regions with substantial JQ1
Chem-seq signal but no significant BRD2, BRD3, or BRD4 ChIP-seq signal and vice versa
(Fig. 2b). We adopted a generalized linear model (GLM method) to identify regions with
differential signal between JQ1 and BET proteins42, 43. We first identified the set of
genomic regions that were enriched for JQ1 Chem-seq or BET protein ChIP-seq signal in
any one of the twelve datasets being considered (3 replicate JQ1 vitro Chem-seq datasets, 3
replicate BRD2 ChIP-seq datasets, 3 replicate BRD3 ChIP-seq datasets, and 3 replicate
BRD4 ChIP-seq datasets). Regions from a dataset that overlapped with regions from another
data set by 1bp were merged together to form a representative region that spans the
combined genomic region. A total of 29,693 regions were identified. The read density in
each region was calculated in units of reads per million mapped reads per bp (rpm/bp) for
each dataset. The edgeR package was used to model technical variation due to noise among
triplicate datasets and the biological variation due to differences in signal between JQ1
Chem-seq and BET protein ChIP-seq datasets42. Sequencing depth and upper-quantile
techniques were used to normalize all twelve datasets together before common and tagwise
dispersions were estimated. The statistical significance of differences between JQ1 Chem-
seq signals and each of BET protein ChIP-seq signals was next calculated using an exact test
and resulting P values were subjected to Benjamini–Hochberg multiple testing correction
(FDR). For robustness, only regions where all triplicates showed significant enrichment of
either ChIP-seq or Chem-seq signal (signal in units of rpm/bp above bottom 5 percentile of
enriched regions) were used for differential signal analyses. This resulted in only 16266,
17556, and 17802 regions being further considered in the pair-wise comparisons of BRD2
vs. JQS, BRD3 vs. JQS, and BRD4 vs. JQS respectively. We only detect only 1 region
showing substantial more JQ1 Chem-seq signal than BRD4 ChIP-seq signal. However, this
region did have enrichment of BRD4 ChIP-seq. These data indicate that, under these
experimental conditions, there is no identifiable off-target interaction that results in JQ1
Chem-seq signal at regions of the genome without BRD4.
Cyclin T1-CDK9 in vitro kinase assay
Life Technologies SelectScreen Profiling service was used to obtain IC50 values for
inhibition by AT7519 versus biotinylated AT7519.
Composite biotinylated psoralen (bio-psoralen) occupancy profile
The transcription start sites of active and inactive genes were aligned at the center in the
composite view of bio-psoralen enrichment. The average Chem-Seq read density of bio-
psoralen and DMSO control around ±1kb centered on the TSS in 50bp bin was calculated in
rpm/bp. The log2 ratio of mean signal of bio-psoralen and DMSO in 50bp bins is plotted.
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Refer to Web version on PubMed Central for supplementary material.
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Chem-seq from intact cells or cellular lysates reveals genomic sites bound by the BET
bromodomain-targeting drug JQ1.
(a) Features of the Chem-seq method in living cells (in vivo, top) and cell lysates (in vitro,
bottom). Top (in vivo): cells are treated with a biotinylated drug to allow drug-target binding
to take place in the cellular context. Formaldehyde treatment cross-links chromatin-
associated proteins to DNA, including drug-target complexes associated with chromatin.
Following cell lysis and sonication, DNA fragments bound to the drug-target complex are
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tenriched using streptavidin beads. Sequencing of the enriched DNA fragments permits
genome-wide identification of the loci to which the drug target binds. Bottom (in vitro): the
biotinylated drug is added to the cell extract, where it binds protein-DNA complexes.
Enrichment of DNA fragments and sequencing is carried out as in the in vivo method.
(b) Chemical structures of JQ1 and its biotinylated version, bio-JQ1.
(c) Effect of JQ1 (black) and bio-JQ1 (red) on MM1.S cell proliferation. Cells were treated
with varying concentrations of drug for 72 h.
(d) Heatmap representation of binding of the individual BET proteins (ChIP-seq, black) and
bio-JQ1 (in vivo and in vitro Chem-seq, red) to the union of all 25,450 regions occupied by
BRD2, BRD3, BRD4 and bio-JQ1. Read density surrounds the center (±5kb) of all occupied
regions, rank ordered from highest to lowest BRD4 occupancy.
(e) Gene tracks showing BRD2, 3, 4 and bio-JQ1 occupancy of a region of chromosome 12.
ChIP-seq reads for BRD2, 3 and 4 (black), Chem-seq reads for biotinylated JQ1 (bio-JQ1,
red) or DMSO vehicle control (blue) are shown. The genome-wide data is plotted in reads
per million per base pair (rpm/bp).
(f) Close-up view of gene tracks showing BRD2, 3 and 4 occupancy (ChIP-seq) and bio-JQ1
occupancy (Chem-seq) across the CCND2 gene locus.
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Genome-wide drug target analysis.
(a) Genome-wide binding averages of BRD2, BRD3, BRD4 (ChIP-seq) and bio-JQ1 (in
vitro Chem-seq) on active enhancers, active promoters and gene bodies in MM1.S cells.
(b) Heatmap showing the similarity of signal distribution between bio-JQ1 (in vitro Chem-
seq) and BET bromodomain proteins BRD2, 3 and 4 (ChIP-seq) by Pearson correlation at
25,693 genomic regions bound by BET proteins and bio-JQ1. Blue reflects high similarity of
signal between of each pair of factors. Factors are arranged and clustered along both axes
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each factor were generated from three independent experiments.
(c) Differential occupancy analysis of bioJQ1 (in vitro Chem-seq) and either BET
bromodomain protein (ChIP-seq). The log ratios of normalized bio-JQ1 in vitro Chem-seq
signal to BRD ChIP-seq signal are plotted for genomic regions identified as enriched for the
presence of bio-JQ1 or either BRD protein. Triplicate ChIP-seq or Chem-seq datasets were
used for each calculation.
(d) Gene tracks showing the FUT8 enhancer, a site identified as bio-JQ1 high/BRD3 low
region identified in (b, lower panel, red). Triplicate datasets were generated for each factor.
(e) Gene tracks surrounding the transcriptional start site (TSS) of the PAGE gene, a ‘BRD3
preferred region’ (BRD3 high/bio-JQ1 low) identified in (b, lower panel, blue).
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Chem-seq reveals genomic occupancy of a protein kinase inhibitor and a DNA-intercalating
drug.
(a) Upper panel: CDK9 occupancy is correlated with the RNA pol II at promoters in MM1.S
cells. Median CDK9 signal at promoters is ranked by increasing RNA pol II occupancy.
Signals are shown in units of reads per million mapped reads per base pair (rpm/bp).
Promoters were binned (50/bin) and a smoothing function was applied to median signals.
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tLower panel: genome-wide binding averages of CDK9 and RNA pol II on active promoters
and gene bodies in MM1.S cells as determined by ChIP-seq analysis.
(b) Gene tracks showing occupancy of the PRCC gene by CDK9 and RNA pol II based on
ChIP-seq data.
(c) Effect of AT7519 treatment on RNA pol II occupancy at the PRCC gene. MM1.S cells
were treated with either DMSO vehicle (blue) or 2 μM AT7519 (brown) for 6 h, followed by
RNA pol II ChIP-seq analysis. Twenty-fold magnifications of the rpm/bp scale of these gene
tracks are shown in the right panel to show the difference in reads for elongating RNA pol
II. TR, RNA pol II traveling ratio.
(d) Genome-wide binding average RNA pol II (ChIP-seq) on active promoters and gene
bodies following treatment of MM1.S cells with DMSO vehicle (blue) or 2 μM of AT7519
(brown) for 6 h. Magnification of the rpm/bp scale at gene bodies is shown in the inset. The
inset includes RNA polymerase II traveling ratio distributions (TR, mean) derived from
MM1.S cells treated with DMSO (blue) or 2 μM AT7519 (red).
(e) Chemical structures of the pan-CDK inhibitor AT7519 and its biotinylated counterpart
bio-AT7519.
(f) In vitro kinase assays with recombinant cyclin T-CDK9 complex in the presence of
increasing concentrations of AT7519 or bio-AT7519. The derived IC50 values for each
compound are shown.
(g) Effect of AT7519 and bio-AT7519 on MM1.S cell proliferation. Cells were treated with
varying concentrations of drug for 72 h as indicated. The derived EC50 values for each
compound are shown.
(h) Heatmap representation of CDK9 (ChIP-seq, green) and bio-AT7519 binding (in vitro
Chem-seq, red) to all CDK9 occupied regions, rank ordered from highest to lowest CDK9
occupancy. Read density surrounds the center (± 5kb) of all occupied regions.
(i) Gene tracks showing occupancy of the PRCC gene locus by bio-AT7519 (red) and
DMSO (vehicle, blue) as assessed by in vitro Chem-seq analysis, and by CDK9 (ChIP-seq,
green).
(j) Chemical structures of psoralen and biotinylated psoralen.
(k) Heatmap representation of RNA pol II (ChIP-seq, black) and bio-psoralen binding (in
vivo Chem-seq, light blue) to all human Refseq genes, rank ordered from highest to lowest
RNA pol II occupancy. Read density surrounds the center (± 5kb) of occupied regions.
(l) Gene tracks centered at the TSS of the PRMT5 gene, showing occupancy of bio-psoralen
(middle panel, light blue) versus DMSO (upper panel) as revealed by in vivo Chem-seq
analysis, together with RNA pol II ChIP-seq data (lower panel, black).
(m) Metagene representation of bio-psoralen in vivo Chem-seq data at ±1kb around the TSS
of active (light blue) and inactive (grey) genes. Log2 ratio of the mean bio-psoralen Chem-
seq signal to mean DMSO signal in 50bp bins is plotted at the x-axis.
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